TECHNOLOGY DEVELOPMENT FOR ISOLATING GPI-ANCHORED GLYCOPROTEINS

分离 GPI 锚定糖蛋白的技术开发

• 批准号: 8363123
• 负责人: J. Michael Pierce
• 金额: $ 3.44万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363123
• 关键词: Binding; Biological Markers; Cells; Clostridium; Disease; Funding; Glycoproteins; Goals; Grant; Malignant Neoplasms; Mining; National Center for Research Resources; Principal Investigator; Proteins; Reagent; Research; Research Infrastructure; Resources; Serum; Source; Techniques; Technology; Tissues; United States National Institutes of Health; Work; alpha Toxin; cost; technology development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This subproject's goal is to develop a technique to identify the class of glycoproteins in cells known as glycosylphosphoinositide-anchored proteins. This class of proteins is known to increase in size during some disease states, such as cancer, both in cancer tissues and in serum, and it is a logical class to mine for potential biomarkers. The reagent we have been working with is the alpha-toxin from Clostridium septicans, which is known to bind some GPI-anchored proteins.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 该子项目的目标是开发一种技术来鉴定细胞中被称为糖基磷酸肌醇锚定蛋白的糖蛋白类。 已知这类蛋白质在某些疾病状态（例如癌症）期间在癌组织和血清中的大小增加，并且它是挖掘潜在生物标志物的合乎逻辑的类别。 我们一直在使用的试剂是来自败血性梭菌的α毒素，已知它可以结合一些GPI锚定蛋白。